Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution

Caplacizumab prevents platelet adhesion and has been approved for acquired thrombotic thrombocytopenic purpura (aTTP). This study was retrospective, including all patients diagnosed with aTTP and treated with caplacizumab since commercial availability in 2019 until 28 February 2021 at a single acade...

Descripción completa

Detalles Bibliográficos
Autores principales: Logothetis, Constantine N., Patel, Ankita, Eatrides, Jennifer, Jaglal, Michael, Haider, Mintallah, Visweshwar, Nathan, Laber, Damian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347784/
https://www.ncbi.nlm.nih.gov/pubmed/34362201
http://dx.doi.org/10.3390/jcm10153418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347784/
https://www.ncbi.nlm.nih.gov/pubmed/34362201
http://dx.doi.org/10.3390/jcm10153418

Ejemplares similares